Abstract:

Avatrombopag（Doptelet®）is an orally administered second generation thrombopoietin recep⁃ tor agonists（TPO⁃RA）approved for the treatment of primary chronic immune thrombocytopenia（CITP）in adult patients who are refractory or have an unsatisfactory response to other treatments，as well as for the treatment of thrombocytopenia in adult patients with chronic liver disease（CLD）scheduled to undergo an invasive procedure and granted Orphan Drug Designation for the treatment of chemotherapy⁃induced thrombocytopenia（CIT）. The data of phase Ⅲ studies indicate that avatrombopag is safe and generally well tolerated in three indications. At present， the research is underway on the efficacy and safety of avatrombopag for the treatment of thrombocytopenia in aplastic anemia（AA）and hemapoietic stem cell transplantation（HSCT）. The clinical application of avatrombopag is reviewed in this article.

Key words:

avatrombopag, clinical development, thrombocytopenia, thrombopoietin receptor ago? nist, chronic liver disease, cancer therapy, aplastic anemia, hemapoietic stem cell transplantation